Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968363 | 0.84 | RXRA (0.53) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 | |
| SCHEMBL27708876 | 0.83 | RXRA (0.44) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 | |
| SCHEMBL8053572 | 0.83 | RXRA (0.47) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 | |
| SCHEMBL1416897 | 0.83 | RXRA (0.44) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 | |
| SCHEMBL14157496 | 0.83 | RXRA (0.44) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 | |
| SCHEMBL10080941 | 0.83 | KDM4E (0.46) | KDM4ETSHRRXRARXRBALDH1A1 | |
| SCHEMBL19171565 | 0.83 | ACHE (0.46) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 | |
| SCHEMBL824148 | 0.83 | KDM4E (0.46) | KDM4ETSHRRXRARXRBALDH1A1 | |
| SCHEMBL14122063 | 0.83 | RXRA (0.44) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 | |
| SCHEMBL3721185 | 0.83 | RXRA (0.44) | KDM4ERXRARXRBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230278991-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382865-A1 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | KDM5A, KDM5B, KDM5C | KDM4E 12/4885TSHR 4103/4885RXRA 2782/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | KDM4E 2875/4885TSHR 3035/4885RXRA 3662/4885 |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | KDM4E 3325/4885TSHR 642/4885RXRA 1216/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | KDM4E 2318/4885TSHR 4834/4885RXRA 3318/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | KDM4E 2973/4885TSHR 1187/4885RXRA 931/4885 |
| US-20230278991-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | KDM4E 3200/4885TSHR 284/4885RXRA 757/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | KDM4E 4285/4885TSHR 94/4885RXRA 1424/4885 |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | KDM4E 1773/4885TSHR 4673/4885RXRA 4576/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | KDM4E 4340/4885TSHR 508/4885RXRA 440/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | KDM4E 2049/4885TSHR 1093/4885RXRA 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.